|Bid||100.88 x 30000|
|Ask||100.98 x 30000|
|Day's Range||99.73 - 99.73|
|52 Week Range||89.48 - 116.87|
|Beta (3Y Monthly)||0.17|
|PE Ratio (TTM)||12.58|
|Forward Dividend & Yield||2.32 (2.29%)|
|1y Target Est||N/A|
In her decade with Genentech, Sandra Horning has served under four CEOs, the most recent one joining March 1.
Shares of AbbVie leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment — a potential rival to drugs from Eli Lilly and Pfizer.
Lilly said Tuesday ahead of the market open that Talz, a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine, met the primary and all major secondary endpoints up to 12 weeks in the Phase 4 IXORA-R study. Taltz has been approved for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and also for adults with psoriatic arthritis.
When Boston University professor Ed Damiano set out to raise a new tranche of funding for a startup last year, his hopes were low: Diabetes device makers were struggling to raise money in a field that was being increasingly dominated by two players.
US diabetes patients are struggling to obtain Eli Lilly’s half-price insulin, which it unveiled shortly before being grilled by Congress about the soaring price of the essential medicine. Only about 3 per cent of insurance claims for Eli Lilly’s insulin were for the cheaper, generic version Insulin Lispro, compared with 97 per cent for its brand name Humalog, according to recent data from GoodRx, an app that tracks drug prices. Many pharmacists do not know that the cheaper version is available — and other patients cannot access it because their insurance or pharmacy benefit manager has not put it on formulary, the list of drugs that are covered.
Drugmaker Eli Lilly said on Thursday early results from a study suggest that Apple Inc devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer's disease dementia and those without symptoms. The study, tested in 113 participants over the age of 60, was conducted by Apple along with Eli Lilly and Evidation Health. The Apple devices were used along with the Beddit sleep monitoring device and digital apps in the study.
Horizon Therapeutics stock popped Wednesday after its gout treatment, Krystexxa, drove a beat and raise in the second quarter. Adjusted Horizon earnings also came in better than expected.
The best pharmaceutical stocks to buy have commonalities: strong Composite Ratings and Relative Strength Ratings.
Eli Lilly (NYSE: LLY ) has announced positive results for Emgality , which is the preventive treatment of chronic and episodic migraine in patients. The drug has met the primary and all key secondary outcomes ...
The drugmaker has been working to retain its dominant position in the diabetes market, as its top-sellers, including insulin injection Humalog, lose market share to rivals, amid political scrutiny over soaring healthcare costs. Lilly is also banking on its newer treatments such as Emgality, which won U.S. approval to treat migraine last year and has been touted as a growth driver for Lilly. Lilly in March agreed to offer a half-priced version of Humalog after coming under intense pressure from U.S. politicians to lower drug costs.
Eli Lilly (NYSE: LLY ) reported quarterly earnings of $1.50 per share, which beat the analyst consensus estimate of $1.45 by 3.45%. This is unchanged from the same period last year. The company reported ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 29) Acasti Pharma Inc (NASDAQ: ACST ) Array Biopharma Inc ...
Eli Lilly and Co reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost patent protection. The drugmaker has been working to retain its position as a leader in diabetes care with newer drugs like Trulicity, Jardiance and Basaglar, as its top-selling insulin product Humalog faces increased competition and political pressure over the soaring cost of life-sustaining insulin. Lilly is counting on new drugs in other therapeutic areas to drive growth, such as Taltz for psoriasis and migraine treatment Emgality, which won U.S. approval last year.
Shares of Eli Lilly & Co. rallied 1.5% in premarket trading Tuesday, after the drug maker reported a second-quarter profit and revenue that beat expectations and raised its full-year outlook. Net income was $1.33 billion, or $1.44 a share, after a loss of $259.9 million, or 25 cents a share, in the same period a year ago. Excluding non-recurring items, adjusted EPS rose to $1.50 from $1.48, above the FactSet consensus of $1.45. Revenue rose 1% to $5.64 billion, beating the FactSet consensus of $5.58 billion. Trulicity sales climbed 32% to $1.03 billion, just below the FactSet consensus of $1.08 billion, while Humalog sales fell 12% to $677.6 million but beat expectations of $659.7 million. For 2019, the company raised its adjusted EPS guidance range to $5.67 to $5.77 from $5.60 to $5.70. The stock has lost 6.1% year to date through Monday, while the SPDR Health Care Select Sector ETF has gained 6.9% and the S&P 500 has rallied 20.5%.